-
公开(公告)号：US11279759B2
公开(公告)日：2022-03-22
申请号：US16570966
申请日：2019-09-13
Applicant: MEDIMMUNE, LLC
Inventor： Srinath Kasturirangan , Changshou Gao , Godfrey Rainey , Michelle Morrow , Claire Louise Dobson , Stacey Drabic , Darren Schofield , Gianluca Carlesso , Kristen Pollizzi , Yariv Mazor , Michael Oberst , Scott A. Hammond , Brian Lobo , Prakash Manikwar , Jonathan Seaman , Simon Dovedi , Ronald Herbst
IPC: C07K16/28
Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
-
公开(公告)号：US10457732B2
公开(公告)日：2019-10-29
申请号：US15588271
申请日：2017-05-05
Applicant: MEDIMMUNE, LLC
Inventor： Srinath Kasturirangan , Changshou Gao , Godfrey Rainey , Michelle Morrow , Claire Louise Dobson , Stacey Drabic , Darren Schofield , Gianluca Carlesso , Kristen Pollizzi , Yariv Mazor , Michael Oberst , Scott A. Hammond , Brian Lobo , Prakash Manikwar , Jonathan Seaman , Simon Dovedi , Ronald Herbst
IPC: C07K16/28
Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
-
公开(公告)号：US10400035B2
公开(公告)日：2019-09-03
申请号：US15820943
申请日：2017-11-22
Applicant: MedImmune, LLC , University of Helsinki
Inventor： Kari Alitalo , Simo Syrjala , Karl Lemstrom , Ching Ching Leow , Ronald Herbst , Jane Connor
IPC: A61K39/395 , A61P37/06 , C07K16/22 , C07K14/515 , A61K39/00
Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
-
公开(公告)号：US09896505B2
公开(公告)日：2018-02-20
申请号：US14509457
申请日：2014-10-08
Applicant: MedImmune, LLC
Inventor： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
IPC: A61K39/395 , C07K16/28 , C07K16/30 , A61K39/00
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
-
公开(公告)号：US20150044227A1
公开(公告)日：2015-02-12
申请号：US14383377
申请日：2013-03-07
Applicant: Kari ALITALO , Simo SYRJALA , Karl M. LEMSTROM , MEDIMMUNE, LLC
Inventor： Kari Alitalo , Simo Syrjala , Karl Lemstrom , Ching Ching Leow , Ronald Herbst , Jane Connor
IPC: A61K39/395
CPC classification number: C07K16/22 , A61K39/3955 , A61K2039/505 , A61P37/06 , C07K14/515 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C12N2799/027
Abstract: The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.
Abstract translation: 本公开涉及抗血管生成素-2（Ang-2）的抗体或其抗原结合片段的方法和用途。 具体地，本公开直接涉及抗Ang2抗体或其抗原结合片段用于治疗缺血。 所公开的方法可用于降低微血管通透性，增加微血管灌注，减少组织中的炎症，以及治疗或改善与缺血和/或再灌注损伤相关的疾病。 所公开的方法也可用于保护固体器官移植组织和治疗或预防慢性组织移植排斥反应。
-
Patent Agency Ranking
6.发明申请HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE 有权人类抗CD19抗体及其在治疗肿瘤，移植和自发性疾病中的应用公开(公告)号：US20130115657A1
公开(公告)日：2013-05-09
申请号：US13661138
申请日：2012-10-26
Applicant: MedImmune, LLC.
Inventor： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'acqua , Ronald Herbst , Anthony Coyle
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
Abstract translation: 本发明提供抗CD19小鼠单克隆抗体的嵌合和人源化形式。 本发明进一步涉及药物组合物，免疫治疗组合物和使用结合人CD19抗原并且可介导ADCC，CDC和/或细胞凋亡以治疗B细胞疾病和病症的治疗性抗体的方法，例如但不 限于B细胞恶性肿瘤，用于治疗和预防自身免疫疾病，以及用于治疗和预防人类移植受体中移植物抗宿主病（GVHD），体液排斥和移植后淋巴增殖性疾病。
-
公开(公告)号：US10975155B2
公开(公告)日：2021-04-13
申请号：US15593869
申请日：2017-05-12
Applicant: MedImmune, LLC
Inventor： Manuel Baca , Stacey Drabic , Peter Emtage , Ronald Herbst
Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).
-
公开(公告)号：US10000553B2
公开(公告)日：2018-06-19
申请号：US14347016
申请日：2012-10-10
Applicant: MedImmune, LLC
Inventor： Anthony Coyle , Manuel Baca , Thomas Thisted , Stacey Drabic , Luba Grinberg , Shabazz Novarra , Vaheh Oganesyan , Ronald Herbst , David Kenneth Spencer
CPC classification number: C07K14/78 , A61K38/39 , C07K16/2875 , C07K2318/20 , C07K2319/21 , C07K2319/30 , C07K2319/31
Abstract: The present invention provides Tenascin-3 FnIII domain-based scaffolds that specifically bind to CD40L. The invention further provides engineered variants with increased affinity for the target. The present invention is also related to engineered scaffolds as prophylactic, diagnostic, or therapeutic agents, in particular for therapeutic uses against SLE and other autoimmune diseases and conditions.
-
公开(公告)号：US20160145335A1
公开(公告)日：2016-05-26
申请号：US14509457
申请日：2014-10-08
Applicant: MedImmune, LLC
Inventor： Melissa Damschroder , Peter Kiener , Herren Wu , William Dall'Acqua , Ronald Herbst , Anthony Coyle
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides chimeric and humanized versions of anti-CD19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
-
公开(公告)号：USRE49908E1
公开(公告)日：2024-04-09
申请号：US17364539
申请日：2021-06-30
Applicant: MedImmune, LLC
Inventor： Srinath Kasturirangan , Changshou Gao , Godfrey Rainey , Michelle Morrow , Claire Louise Dobson , Stacey Drabic , Darren Schofield , Gianluca Carlesso , Kristen Pollizzi , Yariv Mazor , Michael Oberst , Scott A. Hammond , Brian Lobo , Prakash Manikwar , Jonathan Seaman , Simon Dovedi , Ronald Herbst
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K16/2803 , C07K16/2827 , C07K16/2878 , C07K2317/31 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/55 , C07K2317/622 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94
Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.051 seconds)
